Veronica Pezzella

456 total citations · 1 hit paper
16 papers, 231 citations indexed

About

Veronica Pezzella is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Veronica Pezzella has authored 16 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Surgery and 4 papers in Hepatology. Recurrent topics in Veronica Pezzella's work include Colorectal Cancer Treatments and Studies (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Cancer Genomics and Diagnostics (4 papers). Veronica Pezzella is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Cancer Genomics and Diagnostics (4 papers). Veronica Pezzella collaborates with scholars based in France, Switzerland and United States. Veronica Pezzella's co-authors include Alice Boilève, Valérie Boige, Florence Castan, Nathalie Bonichon-Lamichhane, Nathalie Mesgouez‐Nebout, Thierry Conroy, Ludovic Evesque, Xavier Artignan, Olivier Bouché and Matthieu Delaye and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and American Journal of Transplantation.

In The Last Decade

Veronica Pezzella

12 papers receiving 231 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

2024 57 citations Thierry Conroy, Florence Castan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veronica Pezzella France	6	157	143	56	44	30	16	231
Matthew L. Holzner United States	8	158 1.0×	59 0.4×	19 0.3×	34 0.8×	4 0.1×	31	325
David G. Vass United Kingdom	8	109 0.7×	106 0.7×	31 0.6×	68 1.5×	7 0.2×	8	211
Brian Hardaway United States	7	58 0.4×	36 0.3×	16 0.3×	24 0.5×	95 3.2×	22	196
Fabian Rössler Switzerland	6	52 0.3×	77 0.5×	9 0.2×	45 1.0×	5 0.2×	29	171
Yuko Omori Japan	11	142 0.9×	207 1.4×	7 0.1×	73 1.7×	3 0.1×	34	270
Toshiyuki Natsume Japan	9	166 1.1×	102 0.7×	3 0.1×	150 3.4×	12 0.4×	42	313
María Rodríguez–Soler Spain	7	46 0.3×	75 0.5×	4 0.1×	35 0.8×	11 0.4×	10	141
Jiong-Jie Yu China	6	54 0.3×	39 0.3×	8 0.1×	23 0.5×	3 0.1×	13	160
Jacob L. van Dam Netherlands	11	194 1.2×	294 2.1×	7 0.1×	221 5.0×	7 0.2×	26	386
Luigi Addario Italy	9	56 0.4×	36 0.3×	9 0.2×	24 0.5×	2 0.1×	12	328

Countries citing papers authored by Veronica Pezzella

Since Specialization

Citations

This map shows the geographic impact of Veronica Pezzella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Pezzella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Pezzella more than expected).

Fields of papers citing papers by Veronica Pezzella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Pezzella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Pezzella. The network helps show where Veronica Pezzella may publish in the future.

Co-authorship network of co-authors of Veronica Pezzella

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Pezzella. A scholar is included among the top collaborators of Veronica Pezzella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Pezzella. Veronica Pezzella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Boilève, Alice, Franck Audemar, Samuel Le Sourd, et al.. (2025). Treatment Intensification with Hepatic Arterial Infusion Chemotherapy in Patients with Liver-Only Colorectal Metastases Still Unresectable After Systemic Induction Chemotherapy: Exploratory Findings From a Prematurely Closed Multicenter Randomized Phase II Study: SULTAN UCGI 30/PRODIGE 53 (NCT03164655). Annals of Surgical Oncology. 33(2). 1460–1469.

Bourien, Héloïse, Xavier Adhoute, Boris Campillo‐Gimenez, et al.. (2025). A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data. Digestive and Liver Disease. 57(10). 2011–2015.

Mazard, Thibault, François Ghiringhelli, Lananh Nguyen, et al.. (2025). 7MO Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): Final results of the randomised phase II PANIRINOX-UCGI28 study. Annals of Oncology. 36. S6–S7.

Conroy, Thierry, Florence Castan, Pierre-Luc Etienne, et al.. (2024). Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Annals of Oncology. 35(10). 873–881. 57 indexed citations breakdown →

Mazard, Thibault, François Ghiringhelli, Anke Winter, et al.. (2023). LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study. Annals of Oncology. 34. S1270–S1270. 2 indexed citations

Conroy, Thierry, Pierre-Luc Etienne, Emmanuel Rio, et al.. (2023). Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.. Journal of Clinical Oncology. 41(17_suppl). LBA3504–LBA3504. 64 indexed citations

Boilève, Alice, Aline Maillard, Mathilde Wagner, et al.. (2020). Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. BMC Cancer. 20(1). 74–74. 12 indexed citations

Boige, Valérie, Jean‐Pierre Pignon, Mathilde Wagner, et al.. (2019). PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.. Journal of Clinical Oncology. 37(15_suppl). TPS3619–TPS3619.

Guimbaud, Rosine, L. Quéro, V. Vendrely, et al.. (2019). PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial. Annals of Oncology. 30. v322–v322. 1 indexed citations

10.

Mazard, Thibault, François Ghiringhelli, Caroline Mollévi, et al.. (2018). UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. Annals of Oncology. 29. viii204–viii204. 2 indexed citations

11.

Patsouris, Anne, Olivier Trédan, L. Campion, et al.. (2018). An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.. Journal of Clinical Oncology. 36(15_suppl). TPS1112–TPS1112. 3 indexed citations

12.

Patsouris, Anne, Cécile Vicier, L. Campion, et al.. (2017). An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.. Journal of Clinical Oncology. 35(15_suppl). TPS1117–TPS1117. 12 indexed citations

13.

Blay, Jean‐Yves, Claire Cropet, Julien Mazières, et al.. (2016). Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSé Program.. Journal of Clinical Oncology. 34(15_suppl). TPS11620–TPS11620. 2 indexed citations

14.

Janus, Nicolas, Vincent Launay‐Vacher, Laurent Sebbag, et al.. (2014). Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study. Transplant International. 27(9). 931–938. 10 indexed citations

15.

Loupy, Alexandre, Aurélie Cazes, R. Guillemain, et al.. (2011). Very Late Heart Transplant Rejection Is Associated with Microvascular Injury, Complement Deposition and Progression to Cardiac Allograft Vasculopathy. American Journal of Transplantation. 11(7). 1478–1487. 63 indexed citations

16.

Loupy, Alexandre, Aurélie Cazes, R. Guillemain, et al.. (2011). 28 Performance of Routine C4d and C3d Immunostaining on Protocol EMBs in a Prospective and Unselected Cohort of Heart Transplant Patients. The Journal of Heart and Lung Transplantation. 30(4). S17–S17. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact